-
公开(公告)号：US20200164067A1
公开(公告)日：2020-05-28
申请号：US16782811
申请日：2020-02-05
IPC分类号： A61K39/39 , A61P35/00 , A61K39/00 , C07D401/14 , C07D401/12
摘要： Compounds and compositions for selectively inhibiting Akt3 are provided. Methods of using the compounds are also provided. Because Akt3 modulates the suppressive function of natural Tregs and the polarization of induced Tregs, the disclosed compounds are useful for modulating immune responses.
-
公开(公告)号：US10660967B2
公开(公告)日：2020-05-26
申请号：US15790498
申请日：2017-10-23
发明人： Siva Panda
IPC分类号： C07C69/96 , C07C229/08 , C07C229/18 , C07C229/36 , C07C233/25 , C07C233/47 , C07C233/51 , A61K47/54 , A61K9/00 , C07D209/20 , C07C323/58 , C07C323/59 , C07C323/52 , C07C237/06 , C07C243/14 , C07D209/28 , C07C271/22
摘要： Curcumin-based conjugates and methods of use thereof are provided. Pharmaceutical compositions including an effective amount of one or more curcumin conjugates are also provided. In particular embodiments, the compositions are formulated for oral delivery. The conjugates and pharmaceutical compositions thereof can be administered to a subject in need thereof to treat a host of diseases and disorders including but not limited to, cancer, inflammation, and microbial growth.
-
公开(公告)号：US20200054595A1
公开(公告)日：2020-02-20
申请号：US16541247
申请日：2019-08-15
发明人： Stephen D Hsu
IPC分类号： A61K31/353 , A61K47/10 , A61K9/12 , A61K9/00 , A61P31/16
摘要： Modified green tea polyphenol compositions and their methods of use in treating influenza viruses are provided. An exemplary green tea polyphenol composition includes (−)-epigallocatechin-3-gallate that can be esterified with a C1-C30 group in at least one position and a carrier such as glycerol. The modified green tea polyphenol compositions can be used to prevent influenza viruses without coming into contact with the viral cell.
-
公开(公告)号：US10478491B2
公开(公告)日：2019-11-19
申请号：US15300614
申请日：2015-04-02
发明人： Samir Khleif
IPC分类号： A61K39/39 , A61K39/395 , A61K39/00 , A61K9/00 , C07K16/28
摘要： As described below, the present invention features methods for enhancing the efficacy of a tumor antigen in inducing an anti-cancer immune response in a subject by administering an OX40 agonist and an Indoleamine 2,3-dioxygenase (IDO) inhibitor with the tumor antigen.
-
公开(公告)号：US20190240100A1
公开(公告)日：2019-08-08
申请号：US16266253
申请日：2019-02-04
申请人： Augusta University Research Institute, Inc. , Mayo Foundation for Medical Education and Research
发明人： Jack Yu , Babak Baban , Vanessa Hale
IPC分类号： A61H1/00 , A61P1/14 , A61K35/741 , A61K35/747 , A61K35/745 , A61K9/00 , A61K31/733 , A61K31/721 , A61K31/717 , A61K31/702 , A61K31/7012 , A61K31/7016
CPC分类号： A61H1/001 , A61H1/005 , A61H2201/105 , A61K9/0031 , A61K9/0053 , A61K31/7012 , A61K31/7016 , A61K31/702 , A61K31/717 , A61K31/721 , A61K31/733 , A61K35/741 , A61K35/745 , A61K35/747 , A61K2035/115 , A61P1/14
摘要： A method of combining probiotic compositions with whole body vibration therapy for the treatment and inhibition of diabetes is disclosed. The disclosed methods may be used for treating diabetes, normalizing glucose metabolism, and reducing inflammation. The disclosed probiotic compositions in combination with whole body vibration are useful in the treatment and inhibition of diabetes.
-
公开(公告)号：US10292978B2
公开(公告)日：2019-05-21
申请号：US15407659
申请日：2017-01-17
IPC分类号： A61K31/4709 , A61K45/06
摘要： Methods of selectively inhibiting Akt3 are provided. It has been discovered that 4-[(6-nitroquinolin-4-yl)amino]-N-[4-(pyridin-4-ylamino)phenyl]benzamide selectively inhibits Akt3. Because Akt3 modulates the suppressive function of natural Tregs and the polarization of induced Tregs, 4-[(6-nitroquinolin-4-yl)amino]-N-[4-(pyridin-4-ylamino)phenyl]benzamide can be used for modulating immune responses.
-
公开(公告)号：US20190060259A1
公开(公告)日：2019-02-28
申请号：US16106421
申请日：2018-08-21
IPC分类号： A61K31/18 , A61P25/00 , A61K31/336 , A61K31/4178 , A61K31/4184 , A61K9/00 , A61P27/02
摘要： Compositions and methods for treating diabetic retinopathy or symptoms thereof are provided. The disclosed compositions and methods for treating diabetic retinopathy contravene the existing paradigm that Renin-Angiotensin System (RAS) blockade alone can treat, prevent, or reduce diabetic retinopathy. The disclosed compositions and methods include a combination or alternation of EET antagonists and ATI antagonists.
-
公开(公告)号：US10201633B2
公开(公告)日：2019-02-12
申请号：US15532645
申请日：2015-12-07
IPC分类号： A61L27/10 , A61K9/50 , A61Q19/08 , A61K8/02 , C09C1/28 , A61L27/26 , A61L27/54 , A61L27/20 , A61L27/24 , A61L27/34 , A61L27/52 , A61L27/56 , C03C4/00 , C03C11/00
摘要： Compositions and methods for glass composites suitable for tissue augmentation, biomedical, and cosmetic applications are provided. The glass microsphere component of the composites are biologically inert, non-reactive and act as a nearly permanent tissue filler. One embodiment provides a tissue augmentation composite containing an effective amount of solid glass microspheres, hollow glass microspheres, porous wall hollow glass microspheres, or combinations thereof with a suitable biocompatible matrix to serve as a bulking agent when injected into a patient. The compositions can be used for soft or hard tissue augmentation as well as delivery of cargos on demand.
-
公开(公告)号：US20180271870A1
公开(公告)日：2018-09-27
申请号：US15540455
申请日：2015-12-30
发明人： Samir Khleif , Rasha Abu Eid
IPC分类号： A61K31/519 , A61K31/4375 , A61K45/06
CPC分类号： A61K31/519 , A61K31/395 , A61K31/4375 , A61K31/7088 , A61K45/06
摘要： Inhibiting Akt1 and Akt2 but not Akt3 in a subject has been found to be an effective immune therapy that delays the exhaustion of CD8 T cells, prolongs CD8 T cell survival, preserves a remarkably high percentage of TCM cells, and significantly increases TCM proliferative potential upon reencountering antigen. In a preferred embodiment, the Akt1 and Akt2 inhibitors do not inhibit Akt3. Preferred small molecule inhibitors include, but are not limited to MK-2206, AZD5363, (1,3-Dihydro-1-(1-((4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one trifluoroacetate salt hydrate or combinations thereof.
-
公开(公告)号：US20180271364A1
公开(公告)日：2018-09-27
申请号：US15934479
申请日：2018-03-23
CPC分类号： A61B3/113 , A61B3/0058 , A61B3/112 , A61B3/14 , A61B5/4082 , G06F3/013
摘要： A system for identifying abnormal eye movements includes a near-eye display (NED), an eye-tracking camera, a frame supporting the NED and the eye-tracking camera, and a processor in data communication with the NED, the eye-tracking camera, and a computer readable medium. The computer readable medium has instructions thereon. When executed by the processor, the instructions cause the processor to provide a target on the NED to a user's eye and change the target or move the target to a plurality of locations in three dimensions on the NED according to one or more tasks of a task module. The processor further records positional information and pupil information of the user's eye during the one or more tasks of the task module and compares the positional information to at least one threshold value of an abnormality identification algorithm.
-
-
-
-
-
-
-
-
-
搜索结果
162 条记录 (耗时 0.028 秒)
